Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight to 2025 – Non-beneficial Approval of Drugs Is Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–Feb 24, 2021–
The "Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 2025" report has been added to ResearchAndMarkets.com’s offering.
The strategy opted by the BCL-2 inhibitor market and variety of drugs under clinical development are considered to be important steps in changing the overall therapeutic approach for the cancer treatment. The global BCL-2 inhibitor market is categorized as a well-designed, carefully controlled therapeutic market that targets the BCL-2 protein for killing the cancer cells.
Companies Mentioned

  • Abbvie
  • Amgen
  • Novartis
  • Roche
  • AstraZeneca
  • Ascentage Pharma
  • BeiGene
  • Ligand Pharma
  • Tocris Bioscience

Report Highlights:

  • Global BCL-2 Inhibitors Market Opportunity: >US$ 4 Billion by 2025
  • Insight on Market Indicators & Approved Drugs Sales Data
  • Global BCL-2 Inhibitors Market Absolute Growth: >300% ( 97% CAGR, 2018 – 2020)
  • Comprehensive Information On Ongoing Clinical Trials
  • Global BCL-2 inhibitors Clinical Trials By Company, Indication & Phase
  • Venetoclax Is The First Approved Drug Belonging To The Class Of BCL-2 Inhibitor

The total volume of the agents available in the market has gradually increased by a certain amount of percentage and it is witnessed that the market has modestly moved faster in terms of size than any other cancer therapies, which altogether is driven by millions of factors around the world. There has been a substantial increase in the spending of the medicine, which is primarily driven by acceptance of the therapy by the developed markets and increased percentage of pharmerging markets. All the developed markets focused towards the inhibitor therapy have offset increased the production rate as well as commercialization strategies in order to end the struggle of the patients who have not been responding to any other cancer therapies available in the market.
In the past few years, the number of BCL-2 inhibitor drugs that have reached the last stage of the development pipeline is witnessed to gradually impact the current growth rate of overall market. The arrival of novel drugs and expected arrival of novel active substances in the market are estimated to address significant unmet needs of the cancer patients across the globe. In addition to this, the global continued research with respect to the existing mechanism of action of drugs is estimated to cross the spectrum of a well-defined market towards a market that is huge and unavoidable.
The global development of the market in different research centers and bio-pharmaceutical companies is estimated to challenge the current traditional cancer therapies. The market on a brighter side involves complete novel platform that is making the cancer patients observe high overall survival rate, five-year survival years, complete response and progression free survival. Also, association of the market with gene-editing technology such as CRISPR and technologically driven method artificial intelligence are estimated to transform the market by creating a plethora of medical applications. Healthcare advances delivered by the market are expected to treat a wide range of cancer types as well as provide the outcomes that were significantly required by the cancer patients for a long period of time.
Compared to few decades ago with the start of the blooming market, the therapy has observed some real CAGR growth rate progression in different pharmaceutical markets of the world. At global level, the spending for conducting clinical research activities at different sites has increased to huge percentage over the past few years in some of the major pharmaceutical market and is estimated to grow more. Volume of the drugs available in the pharmaceutical markets has also grown to a certain amount over the past few years and is expected to grow more in the upcoming years.
Overall growth of the volume of the drugs available in the market is estimated to be driven by the non-beneficial approval of drugs under other markets that account for majority of the cancer market, as well as the outlook of the healthcare benefits.
Key Topics Covered:
1. Introduction to B Cell Lymphoma-2 (BCL-2) Inhibitors
2. BCL-2 Inhibitors – Mechanism of Action
3. Role of BCL-2 Inhibitors in Cancer Management
4. BCL-2 Inhibitors in Hematological Cancers
4.1 Overview
4.2 Impact of BCL-2 Inhibitors by Type of Hematological Cancer
4.3 Ongoing Research & Development
5. BCL-2 Inhibitors in Lung Cancers
5.1 Potential of BCL-2 Inhibitors as Lung Cancer Therapeutics
5.2 Current Research & Advancements
5.2.1 Venetoclax
5.2.2 Navitoclax
5.2.3 APG-1252
5.2.4 AT-101
6. BCL-2 Inhibitors in Other Cancers
6.1 Role of BCL-2 Inhibitors in Breast Cancer
6.2 BCL-2 Inhibitors for Ovarian Cancer
7. Global BCL-2 inhibitors Clinical Pipeline By Company, Indication & Phase
8. Marketed BCL-2 inhibitor Drug Clinical Insight: Venetoclax (VENCLYXTO)
9. Global BCL-2 Inhibitor Market Analysis
9.1 Market Overview
9.2 Current Market Scenrio
10. BCL-2 Inhibitors Market Regional Segmentation
10.1 US
10.2 Europe – Market Opportunity
10.3 Japan
10.4 China
10.5 Australia
11. Commercially Available BCL-2 Inhibitor Drug: Venclexta
12. BCL-2 Inhibitors Market Clinical Insight
13. Global BCL-2 Inhibitors Market Dynamics
14. Global BCL-2 Inhibitors Market Future Outlook
15. Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/r/fdn3qh
View source version on businesswire.com:https://www.businesswire.com/news/home/20210224005474/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: ONCOLOGY HEALTH PRACTICE MANAGEMENT GENETICS GENERAL HEALTH CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/24/2021 05:29 AM/DISC: 02/24/2021 05:29 AM
http://www.businesswire.com/news/home/20210224005474/en